Trials Sponsors Conditions Drugs Pricing

Conditions

Ocular Hypertension Open-Angle Glaucoma

Outcome Measures

Primary Outcomes (1)

Assessment of changes in ocular symptoms and signs
Ocular symptoms include: irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation. Following signs will be evaluated: tear break-up time, corneal and conjunctival fluorescein staining, blepharitis, conjunctival redness and tear secretion (schirmer test).
From Screening (Visit 1) to12 weeks.

Secondary Outcomes (1)

Secondary outcome measures include the assessment of safety and quality of life parameters.
From Screening (visit 1) to 12 weeks

Study Arms (1)

Open-lable study with one arm

OTHER

Drug: tafluprost

Interventions

tafluprostDrug

prostaglandin analogue

Open-lable study with one arm

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication.
Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Santen Oy
Industrylead

MeSH Terms

Conditions

Ocular HypertensionGlaucoma, Open-Angle

Interventions

tafluprost

Condition Hierarchy (Ancestors)

Eye DiseasesGlaucoma

Study Officials

Evgeniy Egorov, Professor
State Educational Establishment of Higher Professional Education "Russian State Medical University of Federal Service on Surveillance in Healthcare and Social Development of Russian Federation"
PRINCIPAL INVESTIGATOR

Enrollment

185 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 3, 2010

First Posted

March 16, 2010

Study Start

April 2010

Date type not reported

This date has not been verified as actual or estimated.

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Open-lable study with one arm

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Open-lable study with one arm

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record